

Thursday 4 September			
8.15–9.15	Registration and coffee		
9.15–12.00	Conference room: High 1 Opening Session Chair: Jon Thorkell Einarsson and Martina Frodlund (Sweden) Intro, Welcome to Malmö. Jon Thorkell Einarsson (Sweden) Awards from SRRF. Silje Syversen (Norway), Eline Lundgaard (Norway) Industry-sponsored awards. Jon Thorkell Einarsson and Martina Frodlund (Sweden) What's New in RA? Speaker: Carl Turesson (Sweden) What's new in GCA? Speaker: Aladdin Mohammad (Sweden) What's new in SLE? Speaker: Anne Trolldborg (Denmark)		
12.15–13.15	Lunch / Industry sponsored session in Conference room High 1		
	Conference room: High 1	Conference room: Live 1+2	Conference room: Live 3
13.15–14.30	Understanding infection risk in rheumatic diseases Chairs: Laura Kuusalo (Finland) och Meliha Kapetanovic (Sweden) Speakers: Screening and prophylaxis for infections in patients with rheumatic diseases Kimme Hyrich (UK) Infection Risk in Inflammatory Arthritis: Focus on TNFi Therapy Aron Björnsson (Sweden/Iceland) Herpes zoster vaccination in patients with rheumatoid arthritis receiving JAK inhibitors Hanna Källmark (Sweden)	An Update on Renal involvement and new therapies in ANCA associated vasculitis Chairs: Aladdin Mohammad (Sweden) and Johanna Dahlqvist (Sweden) Speakers: New insights into diagnosis and predictive factors in ANCA glomerulonephritis Silke Brix (UK) New Therapies in ANCA associated vasculitis Rona Smith (UK) Abstracts Hanna Lindberg et al. Cardiovascular disease in patients with ANCA-associated vasculitides – a nationwide registry-based study from Sweden; 9450-A-2515	Immunopathology of Rheumatoid Arthritis Chairs: Silje Syversen (Norway) and Alf Kastbom (Sweden) Speaker: Utility of synovial biopsies for guiding treatment of rheumatoid arthritis Felice Rivellese (UK) Abstracts Sundbeck et al. A distinct pattern of T-cell and B-cell subpopulations predicts response to CTLA-4 Ig treatment in early rheumatoid arthritis; 9366-A-2515 Cristina Maglio et al. Acylcarnitine Enrichment as A Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint; 9338-A-2515
14.30–15.00	Coffee		
15.00–16.15	Beyond B-cell depletion - novel therapies in systemic diseases Chairs: Francesca Faustini (Sweden) and Aikaterini Chatzidionysios (Sweden) Speakers: The evolution of B-cell directed therapies: from monoclonal antibodies to cell-based approaches Chris Wincup (UK) CAR-T treatment in autoimmune diseases: current evidences and future perspectives Melanie Hagen (Germany) Abstracts	ILD in the context of rheumatic disorders Chairs: Torkell Ellingsen (Denmark) and Anna-Karin Hultgård-Ekwall (Sweden) Speakers: Respiratory involvement in Rheumatic and CTDs: assesement of drug causality Philippe Camus (France) Treatment of RA associated interstitial lung disease Carl Turesson (Sweden) Abstract Hultgård Ekwall et al. Plasma levels of interferon-alpha are associated with the presence of radiographic airway	Imaging in axial spondylarthritis Chairs: Thorvardur Jon Löve (Iceland) and Tor Olofsson (Sweden) Speakers: Developments in imaging in axial spondyloarthritis Mikkel Østergaard (Denmark) Optimal use of imaging in the management of axial spondyloarthritis Sofia Ramiro (Netherlands) Abstract Johan K Wallman et al. Persistence of gut inflammation in axial spondyloarthritis associated with worse deterioration in spinal mobility over six years – Results from the SPARTAKUS cohort; 9292-A-2515

	Albin Björk et al. Amlexanox inhibits production of type I interferon and suppresses B cell differentiation in vitro: a potential novel therapeutic option for SLE and other systemic inflammatory diseases; 9360-A-2515 Cecilia Fugmann et al. A high polygenic risk score is associated with multiple disease manifestations and MALT lymphoma in Sjögren's disease; 9398-A-2515	abnormalities in early untreated rheumatoid arthritis; 9440-A-2515	
16.15-16.35	Sponsor presentations Chair: Martina Frodlund		
16.35–	NETWORKING in the exhibition area		

Friday 5 September

	Run for Arthritis		
8.15–9.00	Industry sponsored session with breakfast in Conference room High 1		
	Conference room: High 1	Conference room: Live 1+2	Conference room: Live 3
9.10-10.25	Gout, joint and beyond Chair: Lennart Jacobsson (Sweden) Speakers: Gout, cardiovascular risk and the role for SGLT1 Abhishek Abhishek (UK) Management of gout - lessons from the NOR-Gout study Tillman Uhlig (Norway) Gout in the Nordic countries Mats Dehlin (Sweden)	Disease mechanisms and treatment in idiopathic inflammatory myopathies Chairs: Antonella Notarnicola (Sweden) and Helene Alexandersson (Sweden) Speakers: Mechanisms of muscle weakness in inflammatory myopathy Daniel Andersson (Sweden) Exercise as treatment in idiopathic inflammatory myopathies Kristofer M Andreasson (Sweden) Abstracts Angeles S Galindo et al. Advancing Care in Necrotizing Myopathies: Rethinking High-Dose Glucocorticoids for Improved Outcomes in Anti-HMGCR+ Patients; 9370-A-2515 Milica Vranic et al. Identification of differentially expressed genes in patients with Sjögren's disease and incident lymphomas; 9369-A-2515	Inspiring patient and public involvement in research Chair: Monica Persson (Sweden) Inspiring patient and public involvement in research Speakers: Earlier and later learning across my 30+ years of championing patient and public involvement in research Hywel Williams (UK) Developing core outcome sets for SLE in partnership with patients (OMERACT SLE) Ioannis Parodis (Sweden) and Yvonne Enman (Sweden) Being a patient partner in basic research Eva Johansson (Patient Partners, Sweden) Abstract Astrid Jensen Damgaard. Involvement of Patients and Relatives in the Development of a Combined Fatigue Intervention (COMFI) for People with Inflammatory Arthritis; 9383-A-2515
10.25-10.45	Coffee		
10.45–12.00	Comorbidities in Rheumatoid Arthritis Chairs: Dalia Miltiniene (Lithuania) and Lotta Ljung (Sweden)	SLE sub-phenotyping Are all the same? Chairs: Gerdur Gröndal (Iceland) and Karoline Lerang (Norway)	Physical Capacity in RMDs – assessment and exercise for individually tailored care Chairs: Tanja Thomsen (Denmark) and Monica Holmner (Sweden)

	Speakers: Cardiovascular risk management in patients with RA Anna Södergren (Sweden) Malignancy in patients with rheumatoid arthritis - clinical implications from register studies Johan Askling (Sweden) Osteoporosis in patients with RA Glenn Haugeberg (Norway)	Speakers: SLE: From Classification Criteria to Clinical Clusters I Henrik Leffers (Denmark) SLE: From Classification Criteria to Clinical Clusters II Elisabeth Svenungsson (Sweden) Abstracts Isak Samuelsson et al. Association between systemic lupus erythematosus and myocardial infarction subtypes – a matched cohort study in Sweden; 9305-A-2515 Majd Bairkdar et al. Risk of ischemic and non-ischemic heart failure in patients with systemic sclerosis: a population-based study; 9346-A-2515	Speakers: Kasper Yde Jensen (Denmark) Kristine Røren Norden (Norway) Applying VO2peak testing in early myositis Kristofer M Andreasson (Sweden) Annelie Bilberg (Sweden) Abstract: Kasper Yde Jensen Sustained benefits of high-intensity resistance training in myositis, 9429-A-2515.
12.15-13.15	Lunch / Industry sponsored session in Conference room High 1		
13.15-14.30	Recent developments in the treatment of psoriatic arthritis Chairs: Sandra Meisalu (Estonia) and Johan Karlsson Wallman (Sweden) Speaker: Recent developments in the treatment of psoriatic arthritis Laure Gossec (France) Abstracts Vladimirova et al. Sacroiliac joint involvement in psoriatic arthritis –MRI, radiographic and clinical findings in 581 European real-world patients; 9295-A-2515 Kjørholt et al. Clinical characteristics associated with achievement of sustainable drug-free remission in rheumatoid arthritis patients; 9458-A-2515	Complement in rheumatology and APS syndrome Chairs: Saedis Saeverdottir (Sweden) and Anne Trolldberg (Denmark) Speakers: Complement in Rheumatology: A Pathogenic Pathway and a Therapeutic Target Anna Blom (Sweden), Targeting the complement system in antiphospholipid syndrome Aleksandra Antovic (Sweden) Abstract Laila A Alharb et al. The Epidemiology of Primary Antiphospholipid syndrome in Southern Sweden; 9441-A-2515	Psychological well-being in RMD care Chairs: Malin Regardt (Sweden) and Yvonne Enman (Sweden) Speakers: To set the scene Bente Appel Esbensen (Denmark) The big challenge: living with an RMD and experiencing cognitive dysfunction Ingrid de Groot (Netherlands) Beyond the joints: Loneliness and its associations with disease activity and impact in inflammatory arthritis Annette De Thurah (Denmark) Self-management of inflammatory arthritis from the perspective of psychological well-being Luise Holberg Lindgren (Denmark) Abstracts Maria Andersson et al. How do empowerment and lifestyle influence fear-avoidance in patients with long-term RA?; 9330-A-2515 Charlotte Sylwander et al. Knowing the Pain, Embracing Pain, and Building Resilience: Patients' Experiences of a Multimodal Rehabilitation Program for Chronic Pain; 9406-A-2515
14.30-16.00	POSTER EXIBITION		
16.00–16.50	Polymyalgia Rheumatica: Beyond the Pain	Rare diseases in rheumatology and IgG4 syndrome: 2025 Kåre	Practical Strategies for Person-Centered Rheumatology

	Chair: Aladdin Mohammad (Sweden) Speaker: Patient reported outcomes in polymyalgia rheumatica Sarah Mackie (UK) Abstract Fors et al. Predictors of developing Polymyalgia Rheumatica: a nested case-control study based on a population survey; 9109-A-2515	Berglund lecture Chair: Anders Bengtsson (Sweden) Speakers: IgG4-related disease: a 20 years journey Emanuell Della Torre (Italy) When to suspect an autoinflammatory disease and what to do Kari Eklund (Finland)	Chair: Ellen Landgren (Sweden) Speaker: Supporting Person-Centred Leadership across a hospital in Denmark Bibi Hølge-Hazelton (Denmark), Abstract: Ellen Landgren et al. Fostering a sense of security in early RA care through a very tight control clinic – A qualitative study; 9409-A-2515 Expert panel for discussions Susanne Pettersson (Sweden) RN, Associate professor Sigrid Ødegaard (Norway) MD, PhD Jette Primdahl (Denmark) professor
19.00-	Conference dinner (<i>registration is mandatory</i>)		

Saturday 6 September

	Conference room: High 1	Conference room: Live 1+2
8.15–9.00	Industry sponsored session with breakfast in Conference room High 1	
9.30–10.45	Disease mechanisms and treatment in the very early phase of RA Chairs: Solbritt Rantapää-Dahlqvist (Sweden) and Per-Johan Jakobsson (Sweden) Speakers: Experience from treatment of ACPA positive inflammatory arthralgia Andrew P Cope (UK) Mucosal adaptive immunity in the prearthritis phase of RA Alf Kastbom (Sweden) Abstract Bäcklund et al. Diet and the risk of developing rheumatoid arthritis – assessment of dose-response relations based on a nested case-control study; 9448-A-2515	Biomarker discovery in systemic rheumatic diseases Chairs: Martina Frodlund (Sweden) and Henrik Leffers (Denmark) Speakers: The omics approach to unmet needs in rheumatic diseases Sædis Sævarsdóttir (Iceland) Inherited Susceptibility: The Genetic Puzzle of Systemic Rheumatic Diseases Dag Leonard (Sweden) Abstracts Amin Ravaei et al. Metabolomic and transcriptomic alterations in systemic sclerosis skin — a Western Sweden Systemic Sclerosis Project study; 9349-A-2515 Albin Björk et al. A proteomic profile mirrors the salivary gland focus score and disease - associated antibodies in Sjögren's disease 9361-A-2515
10.45–11.15	Coffee	
11.15–12.00	Treatment and cardiovascular risk in RA Chair: Carl Turesson (Sweden) Speaker: Treatment and cardiovascular risk in RA: Anti-rheumatic treatment and cardiovascular risk in patients with rheumatoid arthritis Jon Giles (USA) Abstract Peltonen et al. ERA-CVD study: Subclinical coronary artery disease in patients with new-onset rheumatoid arthritis; 9421-A-2515	
12.00–12.05	Handing over the baton: Introducing the venue for the next SCR congress in 2027 Speaker: Jon Thorkell Einarsson (Sweden)	
12.05–	GRAB AND GO (some macronutrients for the journey home)	